Medicare Overpaid For Prescription Drugs With New Generic Versions Because Of Delay In Incorporating New Prices Into Payment Calculations, HHS OIG Rep
Medicare overpaid for irinotecan, a cancer drug sold by Pfizer under the name Campostar, by $6.5 million in March because of a delay in updating its pricing formula, according to a report released on Tuesday by the HHS Office of Inspector General,
More: continued here
Filed under: Medicare / Medicaid / Tricare on September 8th, 2008